Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 07:55:53 UTC |
---|
Update Date | 2021-09-26 23:02:30 UTC |
---|
HMDB ID | HMDB0250823 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Dacomitinib |
---|
Description | Dacomitinib, also known as vizimpro, belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. Based on a literature review a significant number of articles have been published on Dacomitinib. This compound has been identified in human blood as reported by (PMID: 31557052 ). Dacomitinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Dacomitinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | COC1=C(NC(=O)C=CCN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29) |
---|
Synonyms | Value | Source |
---|
N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enimidate | HMDB | N-(4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-2-butenamide | MeSH | Vizimpro | MeSH |
|
---|
Chemical Formula | C24H25ClFN5O2 |
---|
Average Molecular Weight | 469.95 |
---|
Monoisotopic Molecular Weight | 469.1680809 |
---|
IUPAC Name | N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide |
---|
Traditional Name | N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide |
---|
CAS Registry Number | Not Available |
---|
SMILES | COC1=C(NC(=O)C=CCN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 |
---|
InChI Identifier | InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29) |
---|
InChI Key | LVXJQMNHJWSHET-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinazolinamines |
---|
Alternative Parents | |
---|
Substituents | - Quinazolinamine
- Methoxyaniline
- Anisole
- Aniline or substituted anilines
- N-arylamide
- Alkyl aryl ether
- Chlorobenzene
- Aminopyrimidine
- Halobenzene
- Fluorobenzene
- Piperidine
- Benzenoid
- Imidolactam
- Monocyclic benzene moiety
- Aryl halide
- Aryl fluoride
- Aryl chloride
- Pyrimidine
- Heteroaromatic compound
- Amino acid or derivatives
- Tertiary aliphatic amine
- Carboxamide group
- Tertiary amine
- Secondary carboxylic acid amide
- Azacycle
- Ether
- Carboxylic acid derivative
- Secondary amine
- Organic nitrogen compound
- Organohalogen compound
- Organochloride
- Carbonyl group
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Dacomitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C | 3927.0 | Semi standard non polar | 33892256 | Dacomitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C | 3115.9 | Standard non polar | 33892256 | Dacomitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C | 5355.7 | Standard polar | 33892256 | Dacomitinib,1TMS,isomer #2 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1NC(=O)C=CCN1CCCCC1 | 4059.4 | Semi standard non polar | 33892256 | Dacomitinib,1TMS,isomer #2 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1NC(=O)C=CCN1CCCCC1 | 2862.7 | Standard non polar | 33892256 | Dacomitinib,1TMS,isomer #2 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1NC(=O)C=CCN1CCCCC1 | 5310.1 | Standard polar | 33892256 | Dacomitinib,2TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C | 3720.5 | Semi standard non polar | 33892256 | Dacomitinib,2TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C | 2839.8 | Standard non polar | 33892256 | Dacomitinib,2TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C | 4842.9 | Standard polar | 33892256 | Dacomitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C(C)(C)C | 4102.2 | Semi standard non polar | 33892256 | Dacomitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C(C)(C)C | 3264.8 | Standard non polar | 33892256 | Dacomitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C(C)(C)C | 5350.8 | Standard polar | 33892256 | Dacomitinib,1TBDMS,isomer #2 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1NC(=O)C=CCN1CCCCC1 | 4234.3 | Semi standard non polar | 33892256 | Dacomitinib,1TBDMS,isomer #2 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1NC(=O)C=CCN1CCCCC1 | 2982.8 | Standard non polar | 33892256 | Dacomitinib,1TBDMS,isomer #2 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1NC(=O)C=CCN1CCCCC1 | 5303.2 | Standard polar | 33892256 | Dacomitinib,2TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C(C)(C)C | 4064.5 | Semi standard non polar | 33892256 | Dacomitinib,2TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C(C)(C)C | 3142.7 | Standard non polar | 33892256 | Dacomitinib,2TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1N(C(=O)C=CCN1CCCCC1)[Si](C)(C)C(C)(C)C | 4847.9 | Standard polar | 33892256 |
| Show more...
---|